Entry |
|
Name |
TMPRSS2-ERG fusion to transcriptional activation
|
Definition |
TMPRSS2-ERG => (PLAU,PLAT,MMP3,MMP9,ZEB1,IL1R2) |
Expanded |
2078v1 => (5328,5327,4314,4318,6935,7850) |
Class |
|
Type |
Variant
|
Disease |
|
Gene |
2078 | ERG; ERG, ETS transcription factor |
5328 | PLAU; plasminogen activator, urokinase |
5327 | PLAT; plasminogen activator, tissue type |
4314 | MMP3; matrix metallopeptidase 3 |
4318 | MMP9; matrix metallopeptidase 9 |
6935 | ZEB1; zinc finger E-box binding homeobox 1 |
7850 | IL1R2; interleukin 1 receptor type 2 |
|
Variant |
2078v1 (TMPRSS2-ERG) TMPRSS2-ERG fusion
|
Reference |
|
Authors |
Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R, Cohen Y, Jacob-Hirsch J, Ehrlich M, Ben-Sasson S, Goldfinger N, Loewenthal R, Gazit E, Rotter V, Berger R |
Title |
TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. |
Journal |
|
Reference |
|
Authors |
Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, Gong Y, Cheng H, Laxman B, Vellaichamy A, Shankar S, Li Y, Dhanasekaran SM, Morey R, Barrette T, Lonigro RJ, Tomlins SA, Varambally S, Qin ZS, Chinnaiyan AM |
Title |
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. |
Journal |
|
Reference |
|
Authors |
Squire JA |
Title |
TMPRSS2-ERG and PTEN loss in prostate cancer. |
Journal |
|
|